Vogt-Koyanagi-Harada disease

Street, Duncan; Sivaguru, Arul; Sreekantam, Sreekanth; Mollan, Susan P

doi:10.1136/practneurol-2018-002152

Cited by 15 publications

(38 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the exact etiology remains unknown, TNF-α is regarded as a critical cytokine in the development of uveitis, including However, these studies were case reports with only 1 or 2 patients, and they focused mainly on pediatric patients [7][8][9][10][11].…”

Section: Discussionmentioning

confidence: 99%

“…In 2016, the US FDA granted the indication of ADA in the treatment of noninfectious uveitis. However, only a few case reports have introduced the clinical outcomes of ADA in patients with sight-threatening refractory VKH [7][8][9][10][11][12]. The aim of this study was to evaluate the short-term e cacy and safety of ADA in patients with sightthreatening refractory VKH disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory To Conventional Therapy

Yang¹,

Huang²,

Liu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose To evaluate the short-term effectiveness and safety of adalimumab (ADA) in patients with sight-threatening Vogt-Koyanagi-Harada (VKH) disease refractory to conventional therapy. Methods Medical records of VKH patients who had been treated with systemic glucocorticoids and immunosuppressants but whose condition was poorly controlled were collected and analyzed. Primary outcomes comprised of best-corrected visual acuity (BCVA), intraocular inflammation, relapses, and glucocorticoid-sparing effects. Other outcomes included central macular thickness (CMT), intraocular manifestations and adverse events (AEs). Results Nine refractory VKH patients with a median age of 30 (16, 43) years old were enrolled in this study and received treatment for a median of 10 (7, 11) months. Mean BCVA improved from 0.36 ± 0.26 at baseline to 0.41 ± 0.28 at final visit (P = 0.266). The anterior chamber cell grade decreased from 2 (1.75, 3) + at baseline to 0.5 (0, 1.25) + cell at final visit (P < 0.001). The vitritis grade decreased from 1 (1, 1) + cell at baseline to 0 (0, 1) + cell at final visit (P < 0.001). Patients suffered a median of 1 (0, 2) relapse during treatment. CMT remained stable from 238.50 ± 144.94 µm at baseline to 219.28 ± 77.20 µm at final visit (P = 0.553). The mean prednisone dosage decreased from 21.91 ± 18.39 mg/d to 2.73 ± 4.10 mg/d (P = 0.005). No severe AEs were found during treatment. Conclusions The outcomes indicated that ADA was an effective and safe option for VKH patients refractory to conventional therapy by controlling inflammation, preserving visual function and reducing the daily glucocorticoid dose.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory To Conventional Therapy

Yang¹,

Huang²,

Liu³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…4 Uveitis is relatively common with the incidence of 0.3 to 1.2%. 5 VKHD is an anti-melanocyte granulomatous autoimmune disease that affects eyes, inner ear, meninges, skin, and hair. 5,6 It has been studied that HLA-DR4 is strongly associated with VKHD.…”

Section: Discussionmentioning

confidence: 99%

“…5 VKHD is an anti-melanocyte granulomatous autoimmune disease that affects eyes, inner ear, meninges, skin, and hair. 5,6 It has been studied that HLA-DR4 is strongly associated with VKHD. The clinical features of VKHD include: bilateral chronic iritis, pan uveitis, neurological signs like headache, meningitis, and cutaneous findings of alopecia, poliosis, or vitiligo.…”

Section: Discussionmentioning

confidence: 99%

Vogt – Koyanagi Harada Syndrome in a Pakistani Female

Rebecca¹,

Junejo²,

Shaikh³

et al. 2020

pak J Ophthalmol

View full text Add to dashboard Cite

Vogt-Koyanagi-Harada syndrome is a rare multiorgan inflammatory disorder characterized by bilateral uveitis with serous retinal detachment and is often associated headache, hearing loss, vitiligo, and poliosis. Here we present a case of 37 years old female who presented with chronic photophobia, redness and progressive decreased vision in both eyes for 5 years along with cutaneous and hearing symptoms. On Ocular examination her best-corrected visual acuity was 6/60 OD and perception of light OS, while the intraocular pressure was 16 mm Hg OD and 18 mm Hg OS, measured with Goldmann applanation tonometer. The slit-lamp examination of right anterior segment showed diffuse Keratic precipitates along with diffuse iris atrophy and seclusion pupillae (360 degree). On detailed examination she found to be a case of VKH syndrome. This case is presentedto familiarize ophthalmologists and health care professionals about its findings and complications that are usually found in such patients. Key Words: Uveitis, Poliosis, Vogt Koyanagi Harada, vitiligo.

show abstract

“…In 2016, the US FDA granted the indication of ADA in the treatment of non-infectious uveitis. However, only a few case reports have introduced the clinical outcomes of ADA in patients with sight-threatening refractory VKH (9)(10)(11)(12)(13)(14). The aim of this study was to evaluate the short-term efficacy and safety of ADA in patients with sight-threatening refractory VKH disease.…”

Section: Introductionmentioning

confidence: 99%

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy

et al. 2022

View full text Add to dashboard Cite

Background: No study explores the effectiveness of adalimumab in sight-threatening Vogt-Koyanagi-Harada (VKH) patients in China.Objective: To evaluate the short-term effectiveness and safety of adalimumab (ADA) in patients with sight-threatening Vogt-Koyanagi-Harada (VKH) disease refractory to conventional therapy.Methods: Medical records of VKH patients who had been treated with systemic glucocorticoids and immunosuppressants but whose condition was poorly controlled were collected and analyzed. Primary outcomes comprised of best-corrected visual acuity (BCVA), intraocular inflammation, relapses, and glucocorticoid-sparing effects. Other outcomes included central macular thickness (CMT), intraocular manifestations and adverse events (AEs).Results: Nine refractory VKH patients with a median age of 30 (16, 43) years old were enrolled in this study and received treatment for a median of 10 (7, 11) months. Mean BCVA improved from LogMar 0.63 ± 0.50 (20/72 or 0.36 ± 0.26 in Snellen chart) at baseline to LogMar 0.50 ± 0.37 (20/82 or 0.41 ± 0.28 in Snellen chart) at final visit (P = 0.090). The anterior chamber cell grade decreased from 2 (1.75, 3)+ at baseline to 0.5 (0, 1.25)+ cell at final visit (P < 0.001). The vitritis grade decreased from 1 (1, 1) + cell at baseline to 0 (0, 1)+ cell at final visit (P < 0.001). Patients suffered a median of 1 (0, 2) relapse during treatment. CMT remained stable from 238.50 ± 144.94 μm at baseline to 219.28 ± 77.20 μm at final visit (P = 0.553). The mean prednisone dosage decreased from 21.91 ± 18.39 mg/d to 2.73 ± 4.10 mg/d (P = 0.005). No severe AEs were found during treatment.Conclusions: The outcomes indicated that ADA was an effective and safe option for VKH patients refractory to conventional therapy by controlling inflammation, preserving visual function and reducing the daily glucocorticoid dose.

show abstract

Vogt-Koyanagi-Harada disease

Cited by 15 publications

References 6 publications

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory To Conventional Therapy

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory To Conventional Therapy

Vogt – Koyanagi Harada Syndrome in a Pakistani Female

Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy

Contact Info

Product

Resources

About